Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 951 - 975 of 14670 in total
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Approved
Investigational
Matched Description: … A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong …
Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine...
Approved
Investigational
Matched Description: … a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and ... Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks ... It is active against both active and quiescent cells, although the exact mechanism of action is unknown …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention...
Approved
Matched Description: … considered the most effective and first-line treatment for ADHD in adults and children as recommended ... addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse ... amphetamines, have a high potential for abuse and dependence. …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... , which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Approved
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Aluminum chloride is a chemical compound with the chemical formula AlCl3. When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. It is used in various chemical applications as a Lewis base, with anhydrous aluminium trichloride being the most commonly used Lewis acid....
Approved
Investigational
Matched Categories: … Astringents and Deodorants …
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Barium sulfate is an inorganic compound with the chemical formula BaSO4 . Barium sulfate occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield . This drug is used as a contrast agent in...
Approved
Matched Description: … It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation ... Barium sulfate is ingested by mouth or administered rectally and combined with granules of effervescent ... Therapeutic advantages of barium sulfate in diagnostic procedures include both its low water solubility and
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Description: … A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … peripheral origin, and as an adjuvant in the therapy of epilepsy. ... Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and
Matched Categories: … Calcium-Regulating Hormones and Agents …
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Description: … the eye, ear, nose, and throat. ... It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in ... It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse …
Matched Categories: … Analgesics and Anesthetics …
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … cytokines and growth factors to promote tissue repair [A31818]. ... The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen ... (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells …
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial...
Approved
Investigational
Matched Description: … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023 ... [A263306] It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Description: … adult use and liquid formulation for pediatric use. ... Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is ... used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria …
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Approved
Matched Description: … nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 951 - 975 of 14670 in total